TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Postoperative Pain Control After Periarticular Injection During Total Knee Arthroplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 or older~* Written informed consent~Exclusion Criteria:~* Pregnant women~* Creatinine clearance less than 60 ml/min~* BMI greater than 40~* Currently use greater than 80mg morphine-equivalents daily (pre-operatively)~* Receive a unicondylar knee replacement

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- ROP/KET/CLON/EPI/SAL (Type: EXPERIMENTAL): Ropivacaine (ROP) (5mg/ml)- 50ml Ketorolac (KET) (30mg/ml)- 1ml Clonidine (CLON) (0.1mg/ml)- 0.8ml Epinephrine (EPI) (1mg/ml)- 0.5ml 0.9% sodium chloride SAL)--47.7 ml
- Placebo (Type: PLACEBO_COMPARATOR): 0.9% Sodium Chloride- 100ml

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study to Evaluate Proellex in the Treatment of Premenopausal Women With Symptomatic Endometriosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Premenopausal women aged 18-48 inclusive~* Endometriosis documented by laparoscopic or surgical assessment within the past ten (10) years~* Clinical symptoms of endometriosis for at least the past three (3) months~* Endometriosis symptoms~* Must be sexually active unless sexually inactive for endometriosis-related dyspareunia~* Must have a regular or steady menstrual cycle lasting from 24 to 36 days and a detectable ovulation during the baseline period using an ovulation monitoring kit (for timing of endometrial biopsy)~* Other inclusion criteria may apply~Exclusion Criteria:~* Six (6) months or more without a menstrual period, or~* Prior hysterectomy or~* Prior bilateral oophorectomy~* Diagnosis of osteopenia~* Present history or condition that causes non-endometriosis-related dyspareunia~* Presence of excessive bleeding or menorrhagia~* Abnormal screening endometrial biopsy~* Other exclusion criteria may apply

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 48 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo once daily
- 25 mg (Type: EXPERIMENTAL): Proellex 25 mg once daily
- 50 mg (Type: EXPERIMENTAL): Proellex 50 mg once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Progesterone and Resting Energy Expenditure

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Women during early menopausal transition (MT) with indication for luteal phase progesterone substitution (definition of early MT: change of cycle length (shorter or longer menstrual cycle) of at least ≥ 7 days from normal and/or phases of amenorrhea of up to \< 60 days during the preceding 12 months)~* Body Mass Index (BMI) 18.5 - 24.9 kg/m2~* Informed Consent as documented by signature~Exclusion Criteria:~* Pregnancy or Lactation~* Systemic hormone therapy or hormonal contraception (estradiol, progestogen, androgen) during the study and within 12 weeks prior to study entry~* Phytotherapeutics for menstrual cycle regulation during the study and within 12 weeks prior to study entry~* Active psychiatric disease~* Use of psychotropic drugs during the study and within 12 weeks prior to study entry~* Nicotin abuse \> 10 cigarettes/day~* Alcohol abuse~* Use of appetite suppressants~* Diabetes mellitus~* Untreated Hypo- and hyperthyroidism~* Hypersensitivity to progesterone~* Hypersensitivity to sunflower oil, soy lecithin and other ingredients of Utrogestan® such as gelatine, glycerol, E171 (titanium dioxide)~* Contraindication of progesterone medication according to swissmedicinfo.ch (suspected or diagnosed neoplasia of the breast or other sexual organ; benign or malignant liver Tumors (also in medical history); acute or chronic liver disease (Rotor- or Dubin-Johnson-Syndrome); cholestatic jaundice; porphyria; arterial or venous thromboembolic Events and cerebral bleedings; abnormal genital bleeding of unknown cause)~* Use of barbiturates, antiepileptic drugs, tuberculostatic drugs, antiretroviral drugs, antimycotic drugs, antibiotic drugs, Hypericum perforatum and Spironolactone~* Known or suspected non-compliance, drug or alcohol abuse etc.~* Illiteracy~* Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Utrogestan (Type: EXPERIMENTAL): 300mg Utrogestan (1 tablet 100mg + 1 tablet 200mg)by mouth,every day in the second and third menstrual cycle daily from cycle day 15 to 26.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Post Stroke Fatigue With a Wakefulness Promoting Agent

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age and stroke within 14 days~* Modified Rankin Scale 3 or under and Barthel 85 or over before stroke~* Person that can understand instruction and do tests and questionnaires on their own or with support~* has given informed consent~* MFI-20 score of 12 or more~* Infertile person or fertile women tested negative of pregnancy and using safe anticonception~Exclusion Criteria:~* Dementia or other neuropsychiatric disease making the person incapable of understanding instructions~* Other disease with fatigue as a known symptom~* stroke induced by trauma, infection or surgical procedure~* former drug abuse~* known contraindication to treatment with modafinil~* known active malignancy, benign intracranial tumor, subdural or epidural bleeding~* kidneydysfunction with creatinin more than 265 micromol/L or liver disease with ASAT (aspartate aminotransferase) elevated to more than 70 U/L for women or 100 U/L for men.~* allergy to project treatment~* use of benzodiazepin or antiepileptic drugs in a fixed dose. Sleeping pills not included.~* Patients threaded with ciclosporin or anti HIV medication

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- placebo (Type: PLACEBO_COMPARATOR): placebo
- Modafinil (Type: ACTIVE_COMPARATOR): Modafinil

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: INVSENSOR00011 Clinical Performance Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 18 to 80 years old~* Physical status of ASA I or II~* Must be able to read and communicate in English~* Has signed all necessary related documents, e.g. written informed consent, health assessment questionnaire, gender and ethnicity form, confidentiality agreement~* Passed health assessment screening~Exclusion Criteria:~* Subject has any medical condition which in the judgement of the investigator, renders them inappropriate for participation in the study~* Inability to tolerate sitting still or minimal movement for at least 30 minutes~* Nursing female volunteers~* Excluded at the Principal Investigator's discretion~* Refusal to take pregnancy test (for female subjects)~* Positive pregnancy tests for female subjects of child bearing potential.~* Refusal to shave hair off areas where sensors will be applied (male subjects)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- INVSENSOR00011 Test group (Type: EXPERIMENTAL): The subjects will be enrolled into the test group and will receive the INVSENSOR00011 investigational sensor.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Efficacy, Tolerability and Pharmacokinetics of NNC 0070-0002-0182 in Overweight or Obese Male and Female Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Body mass index (BMI) between 30.0-39.0 kg/m2 (obese)~* Females who consent to using double barrier method of contraception, are post-menopausal and older than 50 years, or have had total hysterectomy~Exclusion Criteria:~* Clinically significant diseases~* Blood pressure greater than 140/90 mmHg~* Evidence of depression~* Recent diet attempts, treatment with diet drugs (within 3 months)~* Liposuction or other surgery for weight loss within the last year~* Evidence of eating disorders (bulimia, binge eating)~* Restricted diets (Kosher, vegetarian)~* Smoker or history of drug or alcohol abuse~* Females of childbearing potential: positive pregnancy test

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- A (Type: EXPERIMENTAL): None
- B (Type: EXPERIMENTAL): None
- C (Type: EXPERIMENTAL): None
- D (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Acandis Credo Intracranial Stent for Unsuccessful Recanalization After Thrombectomy (ACUTE)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Acute ischemic stroke from large vessel occlusion (LVO)~* Failed recanalization after treatment with thrombectomy, i.e. persistent occlusion of intracranial internal carotid artery (ICA), proximal segment (M1, M2) of the middle cerebral artery (MCA) (TICI 0-1)~* Small to moderate infarct core prior to initiation of thrombectomy (CT ASPECTS 6-10, DWI lesion \< 70 ml)~* Suspected underlying stenosis of the occluded artery amenable to stenting by judgement of the treating neurointerventionalist~* Age 18- 80 years~* Informed consent (see below)~* Decision to perform angioplasty and stenting \< 12 hours of symptom onset~* Previous passage of occlusion with microcatheter obtained~Exclusion Criteria:~* Large infarct core prior to initiation of thrombectomy (CT ASPECTS 0-5, DWI lesion \> 70 ml)~* Vessel occlusion or stenosis of different known or suspected cause than atherosclerosis (e.g. vasculitis)~* Pre-stroke disability (MRS \> 2)~* Any sign of intracranial haemorrhage on brain imaging prior to thrombectomy~* Any sign of intracranial vessel perforation during thrombectomy~* Contraindication against treatment with double anti-platelet treatment~* Current effective use of oral anticoagulants (e.g. INR \> 1.7 for Vitamin K antagonists)~* More than 3 attempts for recanalization of target lesion prior to the use of the study device.~* Stenosis longer than the working length of the NeuroSpeed PTA balloon catheter.~* Diameter of the healthy vessel proximal and distal to the stenosis prevents save treatment with the NeuroSpeed PTA balloon catheter or is outside the indicated range of the Credo stent.~* Diameter of the target area is outside the indicated range of the Credo stent after predilation.~* Contraindication against anti-platelet or anticoagulation therapy~* Heavily calcified lesions that may prevent access or safe stent placement.~* Pregnant and breastfeeding women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- ACUTE (Type: OTHER): Patients with acute ischemic stroke and proven large vessel occlusion (e.g. intracranial internal carotid artery or middle cerebral artery) with unsuccessful recanalization after endovascular treatment with mechanical thrombectomy and suspected underlying stenosis of the occluded intracranial artery amenable to stenting based on judgment by the treating neurointerventionalist.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: To Determine the Efficacy of a Laser Device for the Treatment of Hidradenitis Suppurativa

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age equal to or greater than 18 years~* General good health and willingness to participate and ability to comply with the study protocol~* Biopsy proven hidradenitis suppurativa~Exclusion Criteria:~* Age \< 18 years~* Pregnancy~* Hx of collagen vascular or photosensitive disorders~* Inability to follow-up with treatments

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- A (Type: ACTIVE_COMPARATOR): Oral Antibiotics in standard care vs. Laser treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Proton Pump Inhibitor Therapy and Bone Density in Premature Infants

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: None
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Infants born between 24 and 34 weeks gestation and 600g to 2000g birth weight Parental consent has been obtained~Exclusion Criteria:~* Infants with bone disorders, liver or kidney problems, infants of diabetics, growth retarded infants, or infants taking diuretics or chronic steroids will be excluded.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PPI group (Type: None): This group of infants have received treatment with a PPI as ordered by their neonatologist during their hospital stay.
- non-PPI group (Type: None): These infants did not receive PPIs during their hospital stay.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Recombinant Human Growth Hormone (RH-GH) For Accelerating Immune Reconstitution Post Unrelated Cord Blood Transplant

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age ≥12~* \<90 days following Allogeneic Transplantation.~* ANC\>500/ul for 3 consecutive days.~* ≥50% donor cells in all cellular fractions tested.~* No active grade II or higher acute graft versus host disease~* Receiving ≤ 1 mg/kg/day Methylprednisolone or equivalent~* Documentation of morphologic or radiographic remission within 45 days of protocol enrollment~Exclusion Criteria:~* Patients with acute organ dysfunction requiring monitoring in the Intensive Care unit or receiving invasive interventions that may include, Hemodialysis ,CVVHD, or any form of mechanical ventilation including CPAP/BiPap at the time of starting therapy.~* Pregnant or lactating patients and those without a negative pregnancy test.~* Patients must have a life expectancy of at least 3 months.~* Patients must be HIV negative.~* Patients must not be receiving investigational agents for treatment of GVHD.~* Patients with severe veno-occlusive disease as determined by standard criteria.~* Patients with Type 1 Diabetes at the time of initiation of stem cell transplantation.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Reducing Hospital Falls by Empowering Nurses to Provide Ambulatory Aids

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* any one determined to be in need of walking aid and~* Can stand up from a seated position independently without assistance~* Can use ambulatory aid at home without assistance/supervision~* Can sit up in bed AND rise to a standing position independently~Exclusion Criteria:~* Not able to give consent~* Not able to use ambulatory aid independently

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Control (Type: NO_INTERVENTION): No change in the standard of care.
- Fall Prevention Decision Support (Type: EXPERIMENTAL): Nursing assesses patient using the Assistive Device Checklist and provides assistive devices to patients, if appropriate.~Decision support aimed at preventing hospital falls and empowering nurses.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Assessment of Pain Monitoring With ANI/NIPE Monitor Program in Pediatric Cardiac Surgery Postoperative.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* ventilated children admitted in PICU postoperative of cardiac surgery with extracorporeal circulation, consent of the parental control, children benefiting from social security system~Exclusion Criteria:~* Heart rhythm disorder, use of heart rhythm disorder treatments, use of active pacemaker, which make ANI/NIPE values impossible to interpret

- Gender: ALL
- Minimum Age: None
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- : ventilated children (Type: OTHER): ventilated children admitted in PICU postoperative of cardiac surgery with extracorporeal circulation with ANI/NIPE

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Gabapentin on Orthopedic Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Undergoing a hip arthroplasty, total knee arthroplasty, hip fracture repair American Society of Anesthesiologist rating I-III as determined by your anesthesiologist~Exclusion Criteria:~* Pregnancy and breast feeding~  * An allergy to any of the drugs to be used in the study (midazolam, Celecoxib, gabapentin, hydromorphone, bupivacaine)~ * History of a sleep disorder (Obstructive sleep apnea or daytime somnolence)~ * History of taking chronic narcotic pain medications or gabapentin~ * History of rheumatoid arthritis, a psychiatric disorder, or diabetes with impaired renal function~ * History of alcohol or illicit drug abuse.~ * History of a kidney or liver problem.~ * Inability or unwilling to use patient-controlled analgesia.~ * Unable to meet the criteria for removal of the endotracheal tube in the Operating Room~ * History of asthma, hives or an allergic type reaction following an aspirin or other NSAIDS drug such as Ibuprofen.~ * History of stroke or heart attack or thrombotic event within the past 3 months~ * Lactose intolerance~ * History of cardiac surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- placebo (Type: PLACEBO_COMPARATOR): Placebo one dose in the evening of surgery and post op day #1.
- Gabapentin (Type: ACTIVE_COMPARATOR): Gabapentin 400mg orally at 9pm on the evening of surgery and first day post operatively

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study: Rectus Sheath Blocks for Improving Abdominal Surgery Conditions

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Scheduled to undergo an abdominal procedure with a periumbilical or midline incision above the umbilicus~* Age ≥ 18 years.~* American Society of Anesthesiologists physical status class 1 to 3~Exclusion Criteria:~* Known coagulopathy~* Preexisting muscular disease~* Medical conditions contraindicated to bupivacaine, succinylcholine or other medication used in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Bupivacaine (Type: ACTIVE_COMPARATOR): Will have 20ml of bupivacaine injected into each rectus sheath.
- Normal Saline (Type: PLACEBO_COMPARATOR): Will have 20ml of normal saline injected into each rectus sheath.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues